FEATURED COMPANIES
- Aytu BioScience Inc.
- Bracco Diagnostics Inc.
- Curium
- Eli Lilly
- GE Healthcare
- Guerbet Group
Global Imaging Agents Market to Reach $12.9 Billion by 2027
Amid the COVID-19 crisis, the global market for Imaging Agents estimated at US$10.4 Billion in the year 2020, is projected to reach a revised size of US$12.9 Billion by 2027, growing at a CAGR of 3.1% over the analysis period 2020-2027. Diagnostic Radiopharmaceuticals, one of the segments analyzed in the report, is projected to record a 3.5% CAGR and reach US$6.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the X-Ray/CT segment is readjusted to a revised 2.6% CAGR for the next 7-year period.
The U.S. Market is Estimated at $2.8 Billion, While China is Forecast to Grow at 5.8% CAGR
The Imaging Agents market in the U.S. is estimated at US$2.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2027 trailing a CAGR of 5.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0.8% and 2.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.
MRI Segment to Record 2.9% CAGR
In the global MRI segment, USA, Canada, Japan, China and Europe will drive the 2.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1 Billion in the year 2020 will reach a projected size of US$1.2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.8 Billion by the year 2027, while Latin America will expand at a 3.7% CAGR through the analysis period.
Select Competitors (Total 52 Featured):
Amid the COVID-19 crisis, the global market for Imaging Agents estimated at US$10.4 Billion in the year 2020, is projected to reach a revised size of US$12.9 Billion by 2027, growing at a CAGR of 3.1% over the analysis period 2020-2027. Diagnostic Radiopharmaceuticals, one of the segments analyzed in the report, is projected to record a 3.5% CAGR and reach US$6.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the X-Ray/CT segment is readjusted to a revised 2.6% CAGR for the next 7-year period.
The U.S. Market is Estimated at $2.8 Billion, While China is Forecast to Grow at 5.8% CAGR
The Imaging Agents market in the U.S. is estimated at US$2.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2027 trailing a CAGR of 5.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0.8% and 2.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.
MRI Segment to Record 2.9% CAGR
In the global MRI segment, USA, Canada, Japan, China and Europe will drive the 2.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1 Billion in the year 2020 will reach a projected size of US$1.2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.8 Billion by the year 2027, while Latin America will expand at a 3.7% CAGR through the analysis period.
Select Competitors (Total 52 Featured):
- Aytu BioScience Inc.
- Bayer Healthcare Pharmaceuticals
- Bracco Diagnostics Inc.
- Curium
- Daiichi Sankyo Company Limited
- Eli Lilly
- GE Healthcare
- Guerbet Group
- Lantheus Medical Imaging Inc.
- Piramal Imaging SA
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Aytu BioScience Inc.
- Bracco Diagnostics Inc.
- Curium
- Eli Lilly
- GE Healthcare
- Guerbet Group
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
III. MARKET ANALYSIS
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Imaging Agents: Providing Brighter and Clearer Images for Effective Clinical Diagnosis
- Recent Market Activity
- Major Growth Drivers in a Nutshell
- Growing Need for Early Disease Diagnosis Fosters Demand for Imaging Agents
- Select Market Growth Restraints
- Contrast Media: Giving Way to Contemporary Offshoots
- X-ray/CT Segment Continues to Lead Contrast Media Market
- Developed Economies Face Threat from Rising Demand for Contrast Agents in Asia-Pacific
- Diagnostic Radiopharmaceuticals to Outdo Contrast Media
- Nuclear Medicine: A Potential Growth Avenue for Dx Radiopharmaceuticals
- Select PET and SPECT Radioisotopes Used in Nuclear Medicine
- Select Cardiology and Oncology Radiopharmaceuticals
- Developed Markets Rule the Imaging Agents Market, Developing Regions to Spearhead Future Growth
- Impact of Covid-19 and a Looming Global Recession
- Aytu BioScience, Inc. (USA)
- Bayer Healthcare Pharmaceuticals (Germany)
- Bracco Diagnostics, Inc. (USA)
- Curium (France)
- Daiichi Sankyo Company Limited (Japan)
- Bracco-Eisai Co., Ltd (Japan)
- Eli Lilly and Company (USA)
- GE Healthcare (UK)
- Guerbet Group (France)
- Lantheus Medical Imaging, Inc. (USA)
- Piramal Imaging SA (Switzerland)
- Sustained Expansion of Molecular Imaging Platform Presents Positive Outlook
- Novel Radiopharmaceuticals Add New Dimensions to Molecular Imaging
- Latest Radiopharmaceuticals to Benefit Molecular Imaging
- Microbubbles/Ultrasound Contrast Agents Set for Strong Growth
- Growing Interest in Image Guided Surgery Offers New Opportunities
- Role of Near-Infrared Contrast Agents for Image Guided Surgery
- Fluorescence Optical Imaging - Opens New Avenues
- Coronary CT Angiography Opens Up Opportunities for Contrast Agents
- List of Iodine-Containing Contrast Agents for Coronary CT Angiography
- Targeted Imaging - A Game Changer in the Making
- Rising Clinical Acceptance of MRI Systems Augurs Well for Contrast Agents Market
- Researchers Develop Iron Oxide-based Contrast Agent for MRI
- Nanomaterials Taking the Center Stage
- New Nanoparticle Contrast Agents on the Horizon Show Promise
- Gadolinium Coated Nanoparticles - A Promising Imaging Agent
- Growing Focus on Development of Gold Nanoparticles in X-Ray Imaging
- Imaging Agents Make a Welcome Impact in the Field of Alzheimer’s Disease
- List of FDA Approved Alzheimer's Diagnostic Imaging Agents
- Contrast-Enhanced Tomosynthesis Expands Opportunities
- Hyperpolarized Gases as Contrast Agents
- Multi-Modal Imaging: Combating Contrast Medium Inconsistencies
- Falling Prices Turn on the Heat
- Ultrasound Contrast Agents in Diagnosis of Kidney Ailments
- PET: A Prime Growth Driver for Diagnostic Radiopharmaceuticals
- Innovative Radiotracers to Boost Cardiac Applications for SPECT and PET Modalities
- A Peek at Global CVD Stats
- Echocardiography Examinations - Improving Diagnostic Quality through Contrast Agents
- Opportunities on Rise for Fluorine-Based Myocardial Perfusion Agents
- Unfounded Fears of Radiation Exposure: A Major Concern for Nuclear Diagnostics
- Rising Incidence of Cancer - A Major Growth Driver
- World Cancer Statistics - Incidence and Mortality Data
- Improving Healthcare Expenditure to Foster Growth
- Aging Population - A Vital Demography
- A Peek into Pricing Dynamics
- Packaging of Contrast Agents - An Overview
- Global Supply Shortages Restrains Radiopharmaceuticals Market
- Price Sensitivity & Competition from Alternatives
- Lack of Dosage Standards for Pediatric Patients Limits Radiopharmaceutical Efficacy
- Reimbursement Scenario
III. MARKET ANALYSIS
- UNITED STATES
- CANADA
- JAPAN
- CHINA
- EUROPE
- FRANCE
- GERMANY
- ITALY
- UNITED KINGDOM
- SPAIN
- RUSSIA
- REST OF EUROPE
- ASIA-PACIFIC
- AUSTRALIA
- INDIA
- SOUTH KOREA
- REST OF ASIA-PACIFIC
- LATIN AMERICA
- ARGENTINA
- BRAZIL
- MEXICO
- REST OF LATIN AMERICA
- MIDDLE EAST
- IRAN
- ISRAEL
- SAUDI ARABIA
- UNITED ARAB EMIRATES
- REST OF MIDDLE EAST
- AFRICA
- Total Companies Profiled: 52
Note: Product cover images may vary from those shown
- Aytu BioScience Inc.
- Bayer Healthcare Pharmaceuticals
- Bracco Diagnostics Inc.
- Curium
- Daiichi Sankyo Company Limited
- Eli Lilly
- GE Healthcare
- Guerbet Group
- Lantheus Medical Imaging Inc.
- Piramal Imaging SA
Note: Product cover images may vary from those shown
